NCT06630416
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors No drug interventions treatment 2 not_yet_recruiting NCT04294628
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer treatment 1 active_not_recruiting NCT04387656
NCI COVID-19 in Cancer Patients, NCCAPS Study No drug interventions Not Available Not Available active_not_recruiting NCT04514484
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV treatment 1 active_not_recruiting NCT04550494
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations treatment 2 recruiting NCT04704661
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial treatment 1 recruiting NCT04889144
PLAN Intervention to Enhance Engagement of Latino Cancer Patients in Advanced Care Planning No drug interventions supportive_care Not Available recruiting NCT05564377
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial screening 2 recruiting NCT05687110
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes treatment 1 recruiting NCT06311214
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) treatment 2 not_yet_recruiting NCT06364410
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors treatment 1 not_yet_recruiting NCT04197713
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study treatment 1 active_not_recruiting NCT04957615
Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression treatment 2 recruiting NCT05327010
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial treatment 2 recruiting NCT05554341
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial treatment 2 suspended NCT05554380
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial treatment 2 recruiting NCT05638295
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) treatment 2 recruiting NCT05687136
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors treatment 1 recruiting NCT06626256
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma treatment 1 not_yet_recruiting NCT05058339
Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Cancer No drug interventions Not Available Not Available completed NCT06606990
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers treatment 1 not_yet_recruiting NCT06076135
Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors No drug interventions treatment 2 recruiting NCT06223542
Studying TAK-243 in Patients With Advanced Cancer treatment 1 recruiting NCT06328686
Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases No drug interventions treatment 0 recruiting NCT06349642
Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform No drug interventions Not Available Not Available recruiting NCT06549478
Biology-Guided Radiation Therapy for the Treatment of Patients with Bone Metastases No drug interventions treatment 1 recruiting NCT03366103
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors treatment 1 / 2 terminated NCT03428802
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability treatment 2 recruiting NCT04785287
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies treatment 1 / 2 active_not_recruiting NCT01638533
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction treatment 1 active_not_recruiting NCT03502733
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma treatment 1 active_not_recruiting NCT00576654
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery treatment 1 active_not_recruiting NCT03217253
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction treatment 1 withdrawn NCT02387905
Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery in Patients With Solid Tumors and Spinal Metastases No drug interventions treatment 2 active_not_recruiting NCT04317105
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN treatment 1 / 2 active_not_recruiting NCT04514497
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer treatment 1 active_not_recruiting NCT03842228
Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations treatment 1 active_not_recruiting NCT02503709
Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery treatment 1 active_not_recruiting NCT03927885
Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer No drug interventions supportive_care 2 / 3 active_not_recruiting NCT06015932
Group Cognitive Behavior Sessions (CBCSM) to Decrease Distress in Cancer Patients No drug interventions supportive_care Not Available recruiting NCT05371132
Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR) basic_science 1 recruiting NCT05530759
Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal No drug interventions Not Available Not Available recruiting NCT02298959
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer treatment 1 active_not_recruiting NCT03907475
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study) treatment 2 recruiting NCT05733949
Spatiotemporal Stereotactic Body Radiation Therapy for the Treatment of Patients With Polymetastatic Solid Tumors No drug interventions treatment Not Available recruiting NCT02070549
Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction treatment 1 active_not_recruiting NCT03725436
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors treatment 1 active_not_recruiting NCT04372641
Testing the Safety of CB-5339 in Patients With Cancer No drug interventions treatment 1 withdrawn NCT05691517
Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers treatment 1 recruiting NCT04119024
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors treatment 1 recruiting NCT03994796
Genetic Testing in Guiding Treatment for Patients With Brain Metastases treatment 2 recruiting NCT05010096
BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors treatment 1 withdrawn NCT04585958
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer treatment 1 suspended NCT03326258
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery treatment 1 / 2 withdrawn NCT03436563
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability treatment 1 / 2 active_not_recruiting NCT01738139
Ipilimumab and Imatinib Mesylate in Advanced Cancer treatment 1 completed NCT01822522
Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus treatment 1 completed NCT02097225
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery treatment 1 unknown_status NCT02317874
Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer treatment 1 completed NCT04498520
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer treatment 1 withdrawn NCT05222620
SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial No drug interventions treatment 2 recruiting NCT04771520
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors treatment 2 recruiting NCT01902173
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer treatment 1 / 2 active_not_recruiting NCT04800627
Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor treatment 1 / 2 terminated NCT03872427
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study treatment 2 active_not_recruiting NCT02474160
Collection and Storage of Tissue and Blood Samples From Patients With Cancer No drug interventions Not Available Not Available recruiting NCT04820894
Perception of Cure Among Patients With Metastatic Cancer No drug interventions Not Available Not Available withdrawn NCT04329494
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer treatment 1 recruiting NCT04840589
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors treatment 1 recruiting NCT04007744
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors treatment 1 recruiting NCT01366144
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction treatment 1 active_not_recruiting NCT02079740
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors treatment 1 / 2 active_not_recruiting NCT04233567
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations treatment 2 active_not_recruiting NCT02143401
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors treatment 1 active_not_recruiting NCT02321501
Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer treatment 1 active_not_recruiting NCT05728372
64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body Radiation treatment 0 withdrawn NCT04789668
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases treatment 1 / 2 completed NCT04693468
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial treatment 1 recruiting NCT05215769
A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer No drug interventions health_services_research Not Available recruiting NCT05269381
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors treatment 1 / 2 recruiting NCT02419495
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies treatment 1 active_not_recruiting NCT03583255
Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer supportive_care 2 / 3 active_not_recruiting NCT06500455
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain No drug interventions treatment 3 not_yet_recruiting NCT03291938
IACS-010759 in Advanced Cancers No drug interventions treatment 1 completed NCT04021043
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers treatment 1 / 2 active_not_recruiting NCT03237390
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors treatment 1 completed NCT04879121
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors treatment 2 recruiting NCT04960787
Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients and Their Spouses No drug interventions health_services_research Not Available recruiting NCT03065387
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation treatment 1 active_not_recruiting NCT03017833
Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers treatment 1 completed NCT03590054
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies treatment 1 completed NCT05503251
Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases No drug interventions supportive_care Not Available recruiting NCT02710253
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy No drug interventions treatment 2 recruiting NCT04693377
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial No drug interventions supportive_care Not Available recruiting NCT04871477
Adoption of Audio Recording in the Outpatient Supportive Care Center No drug interventions Not Available Not Available not_yet_recruiting NCT03217747
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies treatment 1 / 2 active_not_recruiting NCT04639245
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer treatment 1 / 2 terminated NCT05054998
Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases No drug interventions diagnostic 4 completed NCT06320405
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors treatment 1 / 2 recruiting NCT03080883
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy prevention 3 active_not_recruiting NCT05653661
Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors treatment 1 recruiting NCT02408861
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery treatment 1 recruiting NCT05111561
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer treatment 1 suspended NCT05059678
Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis No drug interventions supportive_care Not Available recruiting NCT03030378
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors treatment 1 active_not_recruiting NCT03229278
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma treatment 1 completed NCT02898207
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer treatment 1 completed NCT03035409
Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors supportive_care 2 active_not_recruiting NCT05101356
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma treatment 1 / 2 recruiting NCT03284385
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 treatment 2 active_not_recruiting NCT05091632
Assessment of Verbal Comprehension and Cognitive Processes in Patients Admitted to the Palliative and Supportive Care Unit No drug interventions Not Available Not Available suspended NCT02721732
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic treatment 2 active_not_recruiting NCT05039632
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies No drug interventions treatment 1 / 2 recruiting NCT04388852
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers treatment 1 recruiting NCT01787500
Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery treatment 1 active_not_recruiting NCT02862275
Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer treatment 1 active_not_recruiting NCT05455606
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment No drug interventions health_services_research Not Available recruiting NCT04090619
Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers No drug interventions Not Available Not Available active_not_recruiting NCT01012817
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer treatment 1 / 2 active_not_recruiting NCT06075524
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types No drug interventions Not Available Not Available recruiting NCT04697524
Integrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced Cancer No drug interventions supportive_care Not Available completed NCT03878524
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial treatment 1 terminated NCT05847686
Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer treatment 1 / 2 active_not_recruiting NCT04729725
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL treatment 1 terminated NCT03525925
Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors treatment 1 completed NCT05095948
Improving Processes of Cancer Care Delivery at a Comprehensive Cancer Center No drug interventions Not Available Not Available not_yet_recruiting NCT04673448
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer treatment 1 recruiting NCT03218826
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery treatment 1 active_not_recruiting NCT02595866
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer treatment 1 completed NCT04539574
An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors No drug interventions diagnostic Not Available active_not_recruiting NCT05472220
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma treatment 1 withdrawn NCT05803382
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers treatment 1 recruiting NCT02595931
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery treatment 1 active_not_recruiting NCT05691491
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness treatment 1 / 2 recruiting NCT02159989
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery treatment 1 completed NCT03682289
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors treatment 2 recruiting NCT04895592
Radiosurgery Before Surgery for the Treatment of Brain Metastases treatment 0 recruiting NCT05564468
Design and Testing of a Web-Based Tool for the Improvement of End-of-Life Planning in Patients With Advanced Cancer No drug interventions supportive_care Not Available recruiting NCT03579446
Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer supportive_care 0 active_not_recruiting NCT04266912
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors treatment 1 / 2 active_not_recruiting NCT03831295
SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies treatment 1 completed NCT03868423
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers treatment 2 withdrawn NCT03184038
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery No drug interventions treatment Not Available recruiting